NetraMark Holdings Inc.

NetraMark Holdings Inc. is a Canada-based technology company specializing in the development of Generative Artificial Intelligence (Gen AI) and Machine Learning (ML) solutions for the pharmaceutical industry. Headquartered in Toronto, Ontario, the company's core mission is to transform clinical trials through AI-powered precision analytics, aiming to enhance the understanding of patient responses and improve the efficiency and success rates of drug development.

The company's primary offering is the NetraAI platform, an advanced machine learning system designed to analyze complex clinical trial data. This platform provides AI-powered insights and software solutions to trial sponsors, clinical research organizations, and biotechnology companies globally. NetraAI utilizes a novel topology-based algorithm to parse patient datasets into strongly related subsets, enabling the identification of meaningful patient subpopulations, optimization of drug development strategies, and reduction of trial failures.

Led by CEO George Achilleos and President Josh Spiegel, with founder Dr. Joseph Geraci serving as CTO/CSO, NetraMark has recently expanded its market presence. The company uplisted to the Toronto Stock Exchange (TSX:AIAI) in February 2026. Recent activities include securing contracts with global biopharmaceutical companies for analyzing Phase 2 depression trial data and supporting analytics for a pivotal Phase 3 clinical trial, as well as an oncology research collaboration. NetraMark is positioned as a specialized solution provider within the pharmaceutical industry, capitalizing on the growing demand for AI-driven healthcare solutions to improve clinical outcomes and regulatory success rates.